comparemela.com

Latest Breaking News On - Prnewswire remegen co ltd - Page 1 : comparemela.com

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88

YANTAI, China, June 3, 2024 /PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-label, multi-center

United statesFang jianminLiu yutaoAmerican society of clinical oncology annual meetingChinese academy of medical sciences cancer hospitalPrnewswire remegen co ltdRemegen coRemegen co ltdAmerican societyClinical oncology annual meetingProfessor liu yutaoChinese academyMedical sciences cancer hospital

Remegen s Innovative New Drug Telitacicept(RC18) Obtains Positive Phase III Results, Submitted for Second Indication for Treatment of Rheumatoid Arthritis

/PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, recently.

United statesJianmin fangPrnewswire remegen co ltdChina national medical products administrationRemegen coNational medical products administrationRemegen co ltdChief scientific officerSullivan reportBrand nameRemegen co

RemeGen s Telitacicept Shows Significant Promise in Phase II Trial for Primary Sjogren s Syndrome: Findings Published in Prestigious Rheumatology Journal

/PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (HKG: 9995, SHA: 688331), a fully-integrated commercial-stage biotechnology company, has.

United kingdomUnited statesZeng xiaofengJianmin fangUnion medical college hospitalDepartment of rheumatologyOxford universityRemegen coBritish society for rheumatologyOxford university pressPrnewswire remegen co ltdBritish societyProfessor zeng xiaofengPeking union medical college hospitalChief scientific officerRemegen co

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

/PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical.

Czech republicUnited statesFang jianminGuo junRemegen coPrnewswire remegen co ltdRemegen co ltdAmerican society of clinical oncologyNational medical products administrationSeagen incUniversity cancer hospitalAmerican societyClinical oncologyAnnual meetingObjective response rateComplete response

ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer

YANTAI, China, June 5, 2023 /PRNewswire/ RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab vedotin (RC48) at this year's American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023, in Chicago. Researchers tested disitamab vedotin and toripalimab in combination on.

United statesCzech republicFang jianminGuo junRemegen coUniversity cancer hospitalAmerican society of clinical oncologyPrnewswire remegen co ltdAmerican societyClinical oncologyAnnual meetingObjective response rateComplete responseDisease control rateProgression free survivalOverall survival

vimarsana © 2020. All Rights Reserved.